< 回列表
Loong Herbert Ho Fung
- Associate Professor (Clinical) – Department of Clinical Oncology The Chinese University of Hong Kong
The Precision Roadmap: Navigating the New Era of HER2-Mutated NSCLC Therapy
| 角色 | 講師 |
| 日期時間 | 05/02 14:50 - 15:30 |
| 地點 | 701B |
學歷 / 訓練
2018, FRCP Edin, Fellow (By Nomination), Royal Colleges of Physicians of Edinburgh, United Kingdom
2016, PDipMDPath , Postgraduate Diploma in Molecular & Diagnostic Pathology, The University of Hong Kong
2013, Clinical Research Fellowship, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada
專業與研究經歷
2021 - Present, Associate Professor (Clinical), Department of Clinical Oncology, The Chinese University of Hong Kong
2025 - Present, Medical Director (Oncology), Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong
獲獎與榮譽
2024
Fellow of the American Society of Clinical Oncology (FASCO), ASCO
2019
Best Poster Award, European Society of Medical Oncology Asia (ESMO Asia) Congress 2019, Singapore
2018
IASLC Foundation Cancer Care Team Award – Awarded for “Best Thoracic Cancer Care in Asia & Rest of World” 2018, International Association for the Study of Lung Cancer **Prestigious international award nominated by lung cancer patients and their caregivers. The CUHK team led by Loong HH received over 10 individual nominations and was bestowed this award for leading the best thoracic cancer care team within the geographical category of “Asia & Rest of World”
重要出版品
- Lam CS, Hua R, Au-Doung LW, Wu YK, Koon HK, Zhou KR, Loong HH, Chung VC, Lee R, Chan A, Cheung YT. Potential supplement-drug interactions and bleeding in patients with cancer: A UK Biobank study. J Integr Med. 2026 Jan;24(1):90-97. d
- Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ. Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. Clin Cancer Res. 2026 Jan 15. doi: 10.1158/1078- 0432.CCR-25-4382. Epub ahead of print. PMID: 41537704.
- Chen ACC, Mok FST, Wong WKY, Lam BHW, Johnson D, Lee MMP, Chan LL, Mo F, Mok KKS, Chen OH, Lee KWC, Loong HHF, Lam KC, Yan K, Mok TSK, Li MSC. Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive nonsmall cell lung cancer treated with first-line osimertinib. Lung Cancer. 2025 Nov 1;210:108808.
- Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, Fang Y, Lu S, Dong X, Wu L, Shinno Y, Daniele G, Yang TY, Kim HR, Ruiter G, Zhao J, Novello S, Miao L, Jänne PA, Goto K, Rüttinger D, Descamps T, Brase JC, Bao W, Li R, Brega N, Grassi P, Girard N, Tan DS; SOHO-01 Investigators. Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025 Oct 17.
- Chan AKY, Chan DTM, Chan JYT, Chen H, Chung NYF, Huang QJQ, Kwan JSH, Li KKW, Li WC, Liu EM, Liu XZ, Loong HHF, Malta TM, Mao Y, Ng HK, Noushmehr H, Poon MFM, Poon WS, Shi ZF, Wang WW, Zhang ZY. Molecular stratification of gliomas using next-generation sequencing: abridged secondary publication. Hong Kong Med J. 2025 Oct;31 Suppl 7(5):18-21. PMID: 41199714.